1.
Dermatol Ther
; 35(8): e15630, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1985782
2.
Dermatol Ther
; 35(7): e15387, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1949122
3.
J Eur Acad Dermatol Venereol
; 36(9): e664-e665, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-1807160
Subject(s)
COVID-19 , Pemphigoid, Bullous , Pemphigus , Humans , Pandemics , Pemphigoid, Bullous/epidemiology , Pemphigus/epidemiology
4.
J Eur Acad Dermatol Venereol
; 35(7): e418-e421, 2021 Jul.
Article
in English
| MEDLINE | ID: covidwho-1135990
5.
Dermatol Ther
; 33(6): e13956, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-632470
ABSTRACT
Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day.